Background: In asthma and chronic obstructive pulmonary disease (COPD), airway mucus hypersecretion contributes to impaired mucociliary clearance, mucostasis and, potentially, the development of mucus plugging of the airways. Summary: Excess mucus production can be targeted via therapies that focus on inhibition mucin synthesis, via reducing expression of mucin (MUC) genes, and/or inhibition of mucin secretion into the airways. Key Messages: This review discusses a number of therapeutic approaches to reduce airway mucus in asthma and COPD, including the use of synthetic and natural products. In particular, it highlights areas where clinical trials of inhibitors of particular target molecules are lacking. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are an example of a targeted therapy that has been researched to reduce mucus synthesis, as have inhibitors of EGFR's downstream signalling pathways, for example, mitogen-activated protein kinase-13 and hypoxia inducible factor-1. However, their efficacy and safety profiles are currently not up to the mark. There is clinical potential in Bio-11006, which reduces mucus secretion via the inhibition of myristoylated alanine-rich C-kinase substrate and is currently in Phase IIb trial.

1.
Rogers DF: Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 2007;52:1134-1146.
2.
Evans CM, Kim K, Tuvim MJ, Dickey BF: Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009;15:4-11.
3.
Evans CM, Koo JS: Airway mucus: the good, the bad, the sticky. Pharmacol Ther 2009;121:332-348.
4.
Rose MC, Voynow JA: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-278.
5.
Ferkol T, Schraufnagel D: The global burden of respiratory disease. Ann Am Thorac Soc 2014;11:404-406.
6.
Burney P, Jarvis D, Perez-Padilla R: The global burden of chronic respiratory disease in adults. Int J Tuberc Lung Dis 2015;19:10-20.
7.
Cazzola M, Page CP, Calzetta L, Matera MG: Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504.
8.
Hakim A, Adcock IM, Usmani OS: Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction. Drugs 2012;72:1299-1312.
9.
Tildy BE, Rogers DF: Therapeutic options for hydrating airway mucus in cystic fibrosis. Pharmacology 2015;95:117-132.
10.
McConnell W, Holgate S: The definition of asthma: its relationship to other chronic obstructive lung diseases; in Clark T, Godfrey S, Lee T, Thomson N (eds): Asthma, ed 4. USA, Arnold, 2000, pp 7-25.
11.
Rubin BK, Priftis KN, Schmidt HJ, Henke MO: Secretory hyperresponsiveness and pulmonary mucus hypersecretion. Chest 2014;146:496-507.
12.
McCarty JC, Ferguson BJ: Identifying asthma triggers. Otolaryngol Clin North Am 2014;47:109-118.
13.
Maslan J, Mims JW: What is asthma? Pathophysiology, demographics, and health care costs. Otolaryngol Clin North Am 2014;47:13-22.
14.
Rothenberg ME, Hogan SP: The eosinophil. Annu Rev Immunol 2006;24:147-174.
15.
Nakagome K, Matsushita S, Nagata M: Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol 2012;158(suppl 1):96-102.
16.
Wang Y, Bai C, Li K, Adler KB, Wang X: Role of airway epithelial cells in development of asthma and allergic rhinitis. Respir Med 2008;102:949-955.
17.
Rogers DF, Barnes PJ: Treatment of airway mucus hypersecretion. Ann Med 2006;38:116-125.
18.
Bradding P, Walls AF, Holgate ST: The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006;117:1277-1284.
19.
Theander K, Hasselgren M, Luhr K, Eckerblad J, Unosson M, Karlsson I: Symptoms and impact of symptoms on function and health in patients with chronic obstructive pulmonary disease and chronic heart failure in primary health care. Int J Chron Obstruct Pulmon Dis 2014;9:785-794.
20.
Hassett DJ, Borchers MT, Panos RJ: Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives. J Microbiol 2014;52:211-226.
21.
Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the medical research council by their committee on the aetiology of chronic bronchitis. Lancet 1965;1:775-779.
22.
van den Berge M, ten Hacken NH, Cohen J, Douma WR, Postma DS: Small airway disease in asthma and COPD: clinical implications. Chest 2011;139:412-423.
23.
MacNee W: Pathology, pathogenesis, and pathophysiology. BMJ 2006;332:1202-1204.
24.
Bradley JR: TNF-mediated inflammatory disease. J Pathol 2008;214:149-160.
25.
Barnes PJ: Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014;35:71-86.
26.
de Oliveira S, Reyes-Aldasoro CC, Candel S, Renshaw SA, Mulero V, Calado A: Cxcl8 (IL-8) mediates neutrophil recruitment and behavior in the zebrafish inflammatory response. J Immunol 2013;190:4349-4359.
27.
Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM: Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006;34:527-536.
28.
Nadel JA, Burgel PR: The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001;1:254-258.
29.
Nadel JA: Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res 2001;2:85-89.
30.
Takeyama K, Dabbagh K, Lee HM, Agustí C, Lausier JA, Ueki IF, et al: Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 1999;96:3081-3086.
31.
Fu XW, Wood K, Spindel ER: Prenatal nicotine exposure increases GABA signaling and mucin expression in airway epithelium. Am J Respir Cell Mol Biol 2011;44:222-229.
32.
Glasser MA: GABAergic system as a target for treatment in asthma. Thorax 2007;62:1080.
33.
Yu H, Li Q, Kolosov VP, Perelman JM, Zhou X: Regulation of cigarette smoke-mediated mucin expression by hypoxia-inducible factor-1α via epidermal growth factor receptor-mediated signaling pathways. J Appl Toxicol 2012;32:282-292.
34.
Polosukhin VV, Cates JM, Lawson WE, Milstone AP, Matafonov AG, Massion PP, et al: Hypoxia-inducible factor-1 signalling promotes goblet cell hyperplasia in airway epithelium. J Pathol 2011;224:203-211.
35.
Crotty Alexander LE, Akong-Moore K, Feldstein S, Johansson P, Nguyen A, McEachern EK, et al: Myeloid cell HIF-1α regulates asthma airway resistance and eosinophil function. J Mol Med 2013;91:637-644.
36.
Adler KB, Tuvim MJ, Dickey BF: Regulated mucin secretion from airway epithelial cells. Front Endocrinol (Lausanne) 2013;4:129.
37.
Agrawal A, Rengarajan S, Adler KB, Ram A, Ghosh B, Fahim M, et al: Inhibition of mucin secretion with MARCKS-related peptide improves airway obstruction in a mouse model of asthma. J Appl Physiol (1985) 2007;102:399-405.
38.
Rogers DF: Motor control of airway goblet cells and glands. Respir Physiol 2001;125:129-144.
39.
Nadel JA, Davis B, Phipps RJ: Control of mucus secretion and ion transport in airways. Annu Rev Physiol 1979;41:369-381.
40.
Dittrich C, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, et al: Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 2002;38:1072-1080.
41.
Hur GY, Lee SY, Lee SH, Kim SJ, Lee KJ, Jung JY, et al: Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation. Exp Mol Med 2007;39:367-375.
42.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A: Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 2015;72:203-218.
43.
Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, et al: Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:438-445.
44.
Alevy YG, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, et al: IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. J Clin Invest 2012;122:4555-4568.
45.
Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139:1470-1479.
46.
Hauber HP, Zabel P: Emerging mucus regulating drugs in inflammatory and allergic lung disease. Inflamm Allergy Drug Targets 2008;7:30-34.
47.
Hauber HP, Daigneault P, Frenkiel S, Lavigne F, Hung HL, Levitt RC, et al: Niflumic acid and MSI-2216 reduce TNF-alpha-induced mucin expression in human airway mucosa. J Allergy Clin Immunol 2005;115:266-271.
48.
Nakano T, Inoue H, Fukuyama S, Matsumoto K, Matsumura M, Tsuda M, et al: Niflumic acid suppresses interleukin-13-induced asthma phenotypes. Am J Respir Crit Care Med 2006;173:1216-1221.
49.
Robichaud A, Tuck SA, Kargman S, Tam J, Wong E, Abramovitz M, et al: Gob-5 is not essential for mucus overproduction in preclinical murine models of allergic asthma. Am J Respir Cell Mol Biol 2005;33:303-314.
50.
Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-525.
51.
Zhou X, Tu J, Li Q, Kolosov VP, Perelman JM: Hypoxia induces mucin expression and secretion in human bronchial epithelial cells. Transl Res 2012;160:419-427.
52.
Tsui L, Fong TH, Wang IJ: The effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) on cell viability under hypoxia. Mol Vis 2013;19:2260-2273.
53.
Van Cutsem E, Köhne C, Hitre E, Zaluski J, Chang Chien C, Makhson A, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
54.
Shen HH, Xu F, Zhang GS, Wang SB, Xu WH: CCR3 monoclonal antibody inhibits airway eosinophilic inflammation and mucus overproduction in a mouse model of asthma. Acta Pharmacol Sin 2006;27:1594-1599.
55.
Ross CL, Hansel TT: New drug therapies for COPD. Clin Chest Med 2014;35:219-239.
56.
Criner G, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, et al: Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014;370:2201-2210.
57.
Marin L, Traini D, Bebawy M, Colombo P, Buttini F, Haghi M, et al: Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies. Eur J Pharm Biopharm 2013;84:566-572.
58.
Zeki AA, Bratt JM, Rabowsky M, Last JA, Kenyon NJ: Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling? Transl Res 2010;156:335-349.
59.
Zeki AA, Franzi L, Last J, Kenyon NJ: Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 2009;180:731-740.
60.
Liou CJ, Cheng PY, Huang WC, Chan CC, Chen MC, Kuo ML, et al: Oral lovastatin attenuates airway inflammation and mucus secretion in ovalbumin-induced murine model of asthma. Allergy Asthma Immunol Res 2014;6:548-557.
61.
Zhu T, Zhang W, Wang DX, Huang NW, Bo H, Deng W, et al: Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor. Chin Med J (Engl) 2012;125:1457-1464.
62.
Neukamm A, Høiseth AD, Einvik G, Lehmann S, Hagve TA, Søyseth V, et al: Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med 2015;278:59-67.
63.
Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA: Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62:1373-1378.
64.
Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT: The use of statins and lung function in current and former smokers. Chest 2007;132:1764-1771.
65.
Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006;97(8 suppl 1):S52-S60.
66.
Zhou E, Fu Y, Wei Z, Yang Z: Inhibition of allergic airway inflammation through the blockage of NF-κB activation by ellagic acid in an ovalbumin-induced mouse asthma model. Food Funct 2014;5:2106-2112.
67.
Alves Cde F, Angeli GN, Favarin DC, de Andrade EL, Chica JE, Faccioli LH, et al: The effects of proresolution of ellagic acid in an experimental model of allergic airway inflammation. Mediators Inflamm 2013;2013:863198.
68.
Chu X, Ci X, He J, Wei M, Yang X, Cao Q, et al: A novel anti-inflammatory role for ginkgolide B in asthma via inhibition of the ERK/MAPK signaling pathway. Molecules 2011;16:7634-7648.
69.
Li MH, Zhang HL, Yang BY: [Effects of ginkgo leave concentrated oral liquor in treating asthma]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1997;17:216-218.
70.
Green TD, Crews AL, Park J, Fang S, Adler KB: Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein? Biochim Biophys Acta 2011;1810:1110-1113.
71.
Van As A, Kraft M, Hanania NA, Parikh I, Murphy EC: Inhibition of airway mucus hypersecretion and inflammation with Bio-11006, a novel dual action drug, results in improvement of indices of bronchitis and lung function in chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2011;183:A4092.
72.
Fang S, Crews AL, Chen W, Park J, Yin Q, Ren XR, et al: MARCKS and HSP70 interactions regulate mucin secretion by human airway epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 2013;304:L511-L518.
73.
Rogers DF: The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options. COPD 2005;2:341-353.
74.
Kannan K, Kanabar P, Schryer D, Florin T, Oh E, Bahroos N, et al: The general mode of translation inhibition by macrolide antibiotics. Proc Natl Acad Sci U S A 2014;111:15958-15963.
75.
Lu S, Liu H, Farley JM Sr: Macrolide antibiotics inhibit mucus secretion and calcium entry in Swine airway submucosal mucous gland cells. J Pharmacol Exp Ther 2011;336:178-187.
76.
Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y: In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003;168:581-587.
77.
Shimizu T, Shimizu S: Azithromycin inhibits mucus hypersecretion from airway epithelial cells. Mediators Inflamm 2012;2012:265714.
78.
Tanabe T, Kanoh S, Tsushima K, Yamazaki Y, Kubo K, Rubin BK: Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells. Am J Respir Cell Mol Biol 2011;45:1075-1083.
79.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al: Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.
80.
Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al: Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-329.
81.
Liu L, Wang GZ, Han D, Li MX: Effectiveness and safety of azithromycin in the treatment of bronchial asthma: a meta-analysis. Nan Fang Yi Ke Da Xue Xue Bao 2015;35:83-87.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.